News | January 31, 2017| Dave Fornell

American College of Cardiology Denounces Trump’s Travel Ban

Travel ban will prevent some cardiologists from attending the one of the largest educational cardiology meetings in the world

ACC, american college of cardiology, impact of Trump travel ban

January 31, 2017 — The American College of Cardiology (ACC) issued a statement against President Donald Trump’s recent executive order banning travel by foreign nationals from seven predominantly Muslim countries. ACC President Richard A. Chazal, M.D., FACC, said the ACC is the professional home for more than 52,000 cardiovascular care professionals from around the world and the travel ban hinders the sharing of science and ideas. 

Trump signed the order the evening of Jan. 27 to keep refugees and other travelers from entering the country for 120 days. The three-month ban includes Iran, Iraq, Syria, Sudan, Libya, Yemen and Somalia.

This ban includes the time of the ACC’s annual scientific sessions, which is one of the largest cardiology conferences in the world and attracts a large number of foreign attendees. More than 13,100 healthcare professionals involved in the delivery of cardiovascular care attend the annual ACC meeting to present or attend education sessions in 41 topic areas.

“This diverse group of scientists, teachers and healthcare professionals are united around the common mission of transforming cardiovascular care and improving heart health with the ultimate goal of curbing the global epidemic of cardiovascular disease,” Chazal said of ACC’s members. “The ability to share ideas and knowledge necessary to address this epidemic is imperative. Policies that impede this free-flow of ideas will have a detrimental impact on scientific discovery, as well as the lives of patients around the world.  If we are to realize a future where cardiovascular disease is no longer the No. 1 killer of men and women worldwide we must ensure that our system of scientific exchange allows for healthcare professionals to learn from each other regardless of their nationality.”

Additionally, Chazal said international medical graduates, naturalized citizens and legal residents make up a significant portion of the healthcare workforce in hospitals and practices across the United States. “For example, more than 25 percent of current practicing physicians are international medical graduates, with cardiology ranking among the top when broken down by medical specialty,” Chazal explained. “Policies that bring the immigration status of those already here into question, while also limiting the ability of others to legally train in the U.S. going forward, will only serve to exacerbate the already existing cardiovascular workforce shortage, especially in rural America. Such policies also threaten the care continuum of patients who rely on these providers for their medical care.”

So far, the ban is affecting fewer than 20 people registered for the annual ACC meeting, March 17-19, 2017, in Washington, D.C., said Nicole Napoli
associate director of ACC media relations. “We’re working with attendees on an individual basis, but to date we’ve had no cancellations because of the ban. Obviously this will continue to develop.”
In his statement, Chazal said the modern-day Hippocratic Oath in part says: "I will respect the hard-won scientific gains of those physicians in whose steps I walk, and gladly share such knowledge as is mine with those who are to follow." It goes on to say: "I will prevent disease whenever I can ... and I will remember that I remain a member of society, with special obligations to all my fellow human beings." 

“The ACC is committed to supporting all of its members — no matter where they live and work, and no matter where they are from — in fulfilling this promise,” Chazal said. 

The Society of Interventional Radiology (SIR) and several other societies also issued statements denouncing the executive order. These societies also released statements explaining the ban will prevent some physicians from the targeted countries from attending the annual society meetings and prevent the free flow of scientific knowledge. SIR said it has 570 international members, and at least two were prevented from attending its meeting March 4–9 in Washington, D.C.

For more information:

Related Content

A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.

Feature | ACC | March 27, 2018 | Dave Fornell
There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American Colle
Drug Stops Dangerous Bleeding in Patients Taking Factor Xa Inhibitors


News | ACC | March 22, 2018
March 22, 2018 — The experimental drug...
Videos | ACC | March 21, 2018
DAIC Editor Dave Fornell takes a tour of some of the most interesting new technologies on the expo floor at
ACC 2018 Late-Breaking Trials Announced
News | ACC | March 21, 2018
Here is a list of the American College of Cardiology (ACC) 2018 annual meeting late-breaking clinical trials presente
Inhaled Therapy Ineffective in Difficult-to-Treat Heart Failure at ACC 2018.

Image from presentation, "Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF: The INDIE-HFpEF Trial," Borlaug

News | ACC | March 20, 2018
March 20, 2018 — Four weeks of treatment with a novel inhaled medication failed to improve exercise capacity, daily a
More Deaths, Strokes Seen with Perioperative Beta Blocker One Year After Surgery

Image from presentation, "1-Year outcomes of perioperative beta-blockade in patients undergoing noncardiac surgery," Devereaux 

News | ACC | March 20, 2018
March 20, 2018 — During the 12 months after undergoing noncardiac surgery, patients with or at risk for heart disease
Trial for Gout Drug Meets Primary Endpoint, Raises Safety Concerns, image shows a CT scan showing gout in the knees.
News | ACC | March 20, 2018
March 20, 2018 — Febuxostat, a gout dr...
Canakinumab Doesn’t Prevent Prediabetes from Progressing to Diabetes according to a late-breaking study at ACC 2018.
News | ACC | March 20, 2018
March 20, 2018 — The anti-inflammatory...
Dabigatran Reduces Major Cardiovascular Complications in Patients With Myocardial Injury after Noncardiac Surgery
News | ACC | March 20, 2018
March 20, 2018 — Treatment with the blood-thinning drug dabigatran significantly reduced the risk of death, heart att
Statins May Bring Benefits at Time of Treatment for Heart Attack, Angina

Image from presentation, "Statins Evaluation in Coronary Procedures and Revascularization," Berwanger 

News | ACC | March 20, 2018
March 20, 2018 — Getting a large dose of a statin did not have an impact on major adverse cardiac events among a broa
Overlay Init